Publication | Open Access

Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

Kras MutationsMedicineReceptor Tyrosine KinasePathologyImportant PredictorsBronchial NeoplasmCancer TreatmentPhosphoinositide-3-kinase Catalytic AlphaOncologyCell BiologyLung Cancer